Effect of estrogen in malignant melanoma.
estrogen
melanocytes
melanoma
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
06
06
2021
accepted:
05
08
2021
pubmed:
21
8
2021
medline:
25
5
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Melanoma is associated with poor prognosis in its advanced stages. Potential influence of estrogen and its metabolites on melanoma growth has been suggested. The objective of this review was to provide an overview on the evidence related to estrogen in malignant melanoma. Literature search using PubMed, Google Scholar and relevant cross-references of the retrieved articles was performed to review relevant published articles related to estrogen and its effects in malignant melanoma. Effect of estrogen signaling on a tissue largely depends on the relative expression of estrogen receptors (ER) α and β. Gender differences in melanoma may be explained by the difference in expression of these receptors. ERβ is the principal ER in melanoma. Although there is uncertainty about role of estrogen in pathogenensis and progression of melanoma, evidence suggests that its growth and metastasis are influenced by estrogen stimulation. Role ER on the proliferation of melanoma cells is well described. There is a need of safe and effective therapy for melanoma, especially for advanced cases. After the establishment of specific role of estrogen and its receptor, analysis of specific genetic mutation can be performed for proper utilization of targeted therapies.
Sections du résumé
BACKGROUND
Melanoma is associated with poor prognosis in its advanced stages. Potential influence of estrogen and its metabolites on melanoma growth has been suggested.
AIMS
The objective of this review was to provide an overview on the evidence related to estrogen in malignant melanoma.
MATERIALS AND METHODS
Literature search using PubMed, Google Scholar and relevant cross-references of the retrieved articles was performed to review relevant published articles related to estrogen and its effects in malignant melanoma.
RESULTS
Effect of estrogen signaling on a tissue largely depends on the relative expression of estrogen receptors (ER) α and β. Gender differences in melanoma may be explained by the difference in expression of these receptors. ERβ is the principal ER in melanoma.
DISCUSSION
Although there is uncertainty about role of estrogen in pathogenensis and progression of melanoma, evidence suggests that its growth and metastasis are influenced by estrogen stimulation. Role ER on the proliferation of melanoma cells is well described.
CONCLUSION
There is a need of safe and effective therapy for melanoma, especially for advanced cases. After the establishment of specific role of estrogen and its receptor, analysis of specific genetic mutation can be performed for proper utilization of targeted therapies.
Substances chimiques
Estrogen Receptor alpha
0
Estrogen Receptor beta
0
Estrogens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1905-1912Informations de copyright
© 2021 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol. 2005;67:335-376.
Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905-931.
Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Struct Lond Engl. 1993;2003(11):741-746.
Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005;336:1023-1027.
Enninga EAL, Moser JC, Weaver AL, et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011. Cancer Med. 2017;6:2203-2212.
Rampen FH. Sex differences in survival from cutaneous melanoma. Int J Dermatol. 1984;23:444-452.
Hofmann MA, Coll SH, Küchler I, et al. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatol Basel Switz. 2007;215:10-16.
Block S, Bonneterre J, Adenis A, Pion JM, Demaille A. Aminoglutethimide in malignant melanoma. A phase II study. Am J Clin Oncol. 1992;15:260-261.
Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol. 2010;204:105-114.
Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat. 2009;89:89-97.
Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884-888.
De Marco P, Bartella V, Vivacqua A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene. 2013;32:678-688.
Kang L, Zhang X, Xie Y, et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol Baltim Md. 2010;24:709-721.
Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005;53:555-568.
Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging. 2007;2:283-297.
Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4038-4044.
Lancet Lond Engl. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 2005;365:1687-1717.
Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol. 2001;159:13-16.
Hartman J, Edvardsson K, Lindberg K, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 2009;69:6100-6106.
Drummond AE, Fuller PJ. The importance of ERbeta signalling in the ovary. J Endocrinol. 2010;205:15-23.
Neil SM, Eves P, Richardson B, et al. Oestrogenic steroids and melanoma cell interaction with adjacent skin cells influence invasion of melanoma cells in vitro. Pigment Cell Res. 2000;13(Suppl 8):68-72.
Dobos J, Tímár J, Bocsi J, et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer. 2004;112:771-776.
de Giorgi V, Mavilia C, Massi D, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol. 2009;145:30-36.
Schmidt AN, Nanney LB, Boyd AS, King LE, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15:971-980.
de Giorgi V, de Giorgi V, Sestini S, et al. Polymorphisms of estrogen receptors: risk factors for invasive melanoma - A prospective study. Oncology. 2011;80:232-237.
Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P. Estrogen receptor β agonists differentially affect the growth of human melanoma cell lines. PLoS One. 2015;10:e0134396.
Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002;119:992-1007.
Thornton MJ. The biological actions of estrogens on skin. Exp Dermatol. 2002;11:487-502.
Boswell W, Boswell M, Titus J, et al. Sex-specific molecular genetic response to UVB exposure in Xiphophorus maculatus skin. Comp Biochem Physiol Toxicol Pharmacol CBP. 2015;178:76-85.
Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62-70.
Grill HJ, Benes P, Manz B, et al. Steroid hormone receptors in human melanoma. Arch Dermatol Res. 1982;272:97-101.
Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NS. Estrogen receptors in patients with malignant melanoma. Cancer. 1980;46:1785-1786.
Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411-423.
Dao H, Kazin RA. Gender differences in skin: a review of the literature. Gend Med. 2007;4:308-328.
Viña J, Borrás C, Gambini J, Sastre J, Pallardó FV. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. FEBS Lett. 2005;579:2541-2545.
Joosse A, De Vries E, van Eijck CH, Eggermont AMM, Nijsten T, Coebergh JWW. Reactive oxygen species and melanoma: an explanation for gender differences in survival? Pigment Cell Melanoma Res. 2010;23:352-364.
Kocarnik JM, Park SL, Han J, et al. Replication of associations between GWAS SNPs and melanoma risk in the Population Architecture Using Genomics and Epidemiology (PAGE) Study. J Invest Dermatol. 2014;134:2049-2052.
Courtenay WH. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med. 1982;2000(50):1385-1401.
Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112:1795-1804.
Mervic L, Leiter U, Meier F, et al. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res. 2011;21:244-252.
Grin CM, Driscoll MS, Grant-Kels JM. The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg. 1998;17:167-171.
Auriemma M, Nicola MD, Varrati S, et al. Mole modifications following controlled ovarian stimulation for assisted reproduction technologies. J Eur Acad Dermatol Venereol. 2015;29:1913-1917.
Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol. 2010;28:287-292.
Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35:215-221.
Kanda N, Watanabe S. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol. 2001;117:274-283.
Dey P, Barros RPA, Warner M, Ström A, Gustafsson J-Å. Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS. J Mol Endocrinol. 2013;51:T61-74.
Renoir J-M, Marsaud V, Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol. 2013;85:449-465.
Lambert WC, Lambert MW, Ring CM, Gagna CE, Espinal-Mariotte JD, Schwartz RA. How Sildenafil (Viagra®) May Cause Melanoma: A Histopathologic Study Providing a Potential Physiological/ Etiopathological Mechanism. J Eur Acad Dermatol Venereol. 2018;32:e202-e204.
Funck-Brentano E, Hélias-Rodzewicz Z, Longvert C, Mokhtari K, Saiag P, Emile J-F. Increase in NRAS mutant allele percentage during metastatic melanoma progression. Exp Dermatol. 2016;25:472-474.
Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One. 2014;9:e91245.
Liu X, Wang L, Chen J, et al. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. Mol Med Rep. 2015;11:1516-1522.
Matsuoka H, Tsubaki M, Yamazoe Y, et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res. 2009;315:2022-2032.
Kanter-Lewensohn L, Girnita L, Girnita A, et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol. 2000;165:131-137.
Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer. 2003;98:1355-1361.
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:1743-1751.
Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999;85:1979-1984.
Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:2745-2751.
Mitkov M, Joseph R, Copland J. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015;417:94-102.
de Giorgi V, Gori A, Grazzini M, et al. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther. 2011;11:739-747.
Leitman DC, Paruthiyil S, Vivar OI, et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol. 2010;10:629-636.
Christoforou P, Christopoulos PF, Koutsilieris M. The role of estrogen receptor β in prostate cancer. Mol Med Camb Mass. 2014;20:427-434.
Williams C, DiLeo A, Niv Y, Gustafsson J-Å. Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett. 2016;372:48-56.
Russo A, Cardile V, Lombardo L, Vanella L, Acquaviva R. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J Nutr Biochem. 2006;17:103-108.
Hajirahimkhan A, Simmler C, Yuan Y, et al. Evaluation of estrogenic activity of licorice species in comparison with hops used in botanicals for menopausal symptoms. PLoS One. 2013;8:e67947.
Singh V, Sharma V, Verma V, et al. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. Eur J Nutr. 2015;54:1255-1267.
Sareddy GR, Nair BC, Gonugunta VK, et al. Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther. 2012;11:1174-1182.
Farina HG, Pomies M, Alonso DF, Gomez DE. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep. 2006;16:885-891.
Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol. 2008;283:49-57.
Shi H, Wu Y, Wang Y, et al. Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. Nutr Cancer. 2015;67:761-770.
Boonmuen N, Gong P, Ali Z, et al. Licorice root components in dietary supplements are selective estrogen receptor modulators with a spectrum of estrogenic and anti-estrogenic activities. Steroids. 2016;105:42-49.
Song NR, Lee E, Byun S, et al. Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma. Cancer Prev Res Phila Pa. 2013;6:1293-1303.
Rossi T, Benassi L, Magnoni C, Ruberto AI, Coppi A, Baggio G. Effects of glycyrrhizin on UVB-irradiated melanoma cells. Vivo Athens Greece. 2005;19:319-322.
Park SY, Kim EJ, Choi HJ, et al. Anti-carcinogenic effects of non-polar components containing licochalcone A in roasted licorice root. Nutr Res Pract. 2014;8:257-266.
Pal HC, Hunt KM, Diamond A, Elmets CA, Afaq F. Phytochemicals for the Management of Melanoma. Mini Rev Med Chem. 2016;16:953-979.
Das S, Das J, Samadder A, Boujedaini N, Khuda-Bukhsh AR. Apigenin-induced apoptosis in A375 and A549 cells through selective action and dysfunction of mitochondria. Exp Biol Med Maywood NJ. 2012;237:1433-1448.
Seidlová-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol. 2003;86:179-188.
Lee M-H, Huang Z, Kim DJ, et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev Res Phila Pa. 2013;6:455-465.
Li L-H, Wu L-J, Jiang Y-Y, et al. Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells. J Asian Nat Prod Res. 2007;9:593-602.
Vaid M, Singh T, Prasad R, Katiyar SK. Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis. Mol Carcinog. 2015;54:1328-1339.
Li L-H, Wu L-J, Zhou B, et al. Silymarin prevents UV irradiation-induced A375-S2 cell apoptosis. Biol Pharm Bull. 2004;27:1031-1036.
Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene. 2008;27:3986-3998.